Nanobiotix Receives Approval From ANSM to Start New Clinical Trial With Lead Product NBTXR3
6/13/2013 8:53:47 AM
More...
|
Nanobiotix' NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma
6/3/2013 9:31:40 AM
More...
|
Nanobiotix' Revenue for the 1st Quarter of 2013
5/15/2013 11:47:52 AM
More...
|
Nanobiotix: 2012 Annual Results
4/25/2013 11:54:43 AM
More...
|
Dr. Laurent Levy, CEO of Nanobiotix, Receives the UB Entrepreneurship Award From the University at Buffalo, SUNY
4/3/2013 11:27:11 AM
More...
|
Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference
3/19/2013 11:37:25 AM
More...
|
Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board
2/13/2013 6:20:46 AM
More...
|
Brainloop Supports Major Licensing Deal for Nanobiotix With Its Secure Dataroom
12/13/2012 10:30:57 AM
More...
|
Nanobiotix: Phase I Independent Data Monitoring Committee Confirms Good Safety of NBTXR3 in the First Group of Patients With Advanced Soft Tissue Sarcoma
11/13/2012 9:09:34 AM
More...
|
PharmaEngine, Inc. Nabs Rights to Nanobiotix's Nanoparticle Radiotherapy Booster for Up to $57 Million
8/6/2012 7:54:44 AM
More...
|
|